Telix Pharmaceuticals (TLX) administered the first patient dose in an early trial of TLX300-CDx, also known as olaratumab, to treat advanced metastatic soft tissue sarcoma.
The trial aims to evaluate the drug's safety, how it moves through and interacts with the body, and the distribution of radiation within tissues, as well as determine the optimal dose, the company said Tuesday in a statement.
Additionally, the trial will help finalize the choice of therapeutic radionuclide to pair with the drug candidate, the company said.
TLX300-CDx hasn't received marketing authorization in any jurisdiction, the company said.
Price: 16.71, Change: -0.05, Percent Change: -0.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。